These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24427340)

  • 1. Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.
    Tatsumi S; Matsuoka H; Hashimoto Y; Hatta K; Maeda K; Kamoshida S
    Int J Clin Exp Pathol; 2014; 7(1):204-12. PubMed ID: 24427340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy.
    Tashiro A; Tatsumi S; Takeda R; Naka A; Matsuoka H; Hashimoto Y; Hatta K; Maeda K; Kamoshida S
    Am J Cancer Res; 2014; 4(5):528-36. PubMed ID: 25232494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
    Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
    PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Okazaki S; Schirripa M; Loupakis F; Cao S; Zhang W; Yang D; Ning Y; Berger MD; Miyamoto Y; Suenaga M; Iqubal S; Barzi A; Cremolini C; Falcone A; Battaglin F; Salvatore L; Borelli B; Helentjaris TG; Lenz HJ
    Cancer; 2017 Nov; 123(22):4506-4514. PubMed ID: 28708932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
    Ozaslan E; Duran AO; Bozkurt O; Inanc M; Ucar M; Berk V; Karaca H; Elmali F; Ozkan M
    Asian Pac J Cancer Prev; 2015; 16(7):2833-8. PubMed ID: 25854370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
    Wen F; Tang R; Sang Y; Li M; Hu Q; Du Z; Zhou Y; Zhang P; He X; Li Q
    Cancer Sci; 2013 Oct; 104(10):1330-8. PubMed ID: 23822592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
    Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
    Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
    Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
    Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
    Tarpgaard LS; Guren TK; Glimelius B; Christensen IJ; Pfeiffer P; Kure EH; Sorbye H; Ikdahl T; Yilmaz M; Johansen JS; Tveit KM
    PLoS One; 2014; 9(2):e87746. PubMed ID: 24498368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
    Matsusaka S; Zhang W; Cao S; Hanna DL; Sunakawa Y; Sebio A; Ueno M; Yang D; Ning Y; Parekh A; Okazaki S; Berger MD; Ichikawa W; Mizunuma N; Lenz HJ
    Mol Cancer Ther; 2016 Jun; 15(6):1405-11. PubMed ID: 26983880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
    Martinez-Balibrea E; Martínez-Cardús A; Musulén E; Ginés A; Manzano JL; Aranda E; Plasencia C; Neamati N; Abad A
    Int J Cancer; 2009 Jun; 124(12):2905-10. PubMed ID: 19296535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
    Park JH; Kim NS; Park JY; Chae YS; Kim JG; Sohn SK; Moon JH; Kang BW; Ryoo HM; Bae SH; Choi GS; Jun SH
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1135-42. PubMed ID: 20091185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
    Morrow CJ; Ghattas M; Smith C; Bönisch H; Bryce RA; Hickinson DM; Green TP; Dive C
    Cancer Res; 2010 Jul; 70(14):5931-41. PubMed ID: 20551056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
    Nakayama G; Tanaka C; Uehara K; Mashita N; Hayashi N; Kobayashi D; Kanda M; Yamada S; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Ando Y; Kodera Y
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):847-55. PubMed ID: 24577566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
    Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Reboredo M; Manzano JL; Rivera F; Safont MJ; Montagut C; González E; Benavides M; Marcuello E; Cervantes A; Martínez de Prado P; Fernández-Martos C; Arrivi A; Bando I; Aranda E;
    PLoS One; 2012; 7(10):e47345. PubMed ID: 23174912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
    Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
    Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy.
    Lin GN; Liu PP; Liu DY; Peng JW; Xiao JJ; Xia ZJ
    Chin J Cancer; 2016 Jan; 35():5. PubMed ID: 26740116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
    Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
    Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.